Clostridioides difficile infection: Clinical sciences

1,281views

Clostridioides difficile infection: Clinical sciences

Academia Infectología

Academia Infectología

Cell wall synthesis inhibitors: Penicillins
Mechanisms of antibiotic resistance
Cell wall synthesis inhibitors: Cephalosporins
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Miscellaneous protein synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
Sepsis: Clinical sciences
Upper respiratory tract infections: Clinical sciences
Influenza: Clinical sciences
Community-acquired pneumonia: Clinical sciences
Tuberculosis (pulmonary): Clinical sciences
Tuberculosis (extrapulmonary and latent): Clinical sciences
COVID-19: Clinical sciences
Rabies virus
Cellulitis and erysipelas: Clinical sciences
Skin abscess: Clinical sciences
Necrotizing soft tissue infections: Clinical sciences
Varicella zoster virus
Herpes zoster infection (shingles): Clinical sciences
Diarrhea: Clinical
Herpes simplex virus
Clostridioides difficile infection: Clinical sciences
Hepatitis A and E: Clinical sciences
Hepatitis B: Clinical sciences
Hepatitis C: Clinical sciences
Lower urinary tract infection: Clinical sciences
Pyelonephritis: Clinical sciences
Treponema pallidum (Syphilis)
Neisseria gonorrhoeae infection: Clinical sciences
Septic arthritis: Clinical sciences
Infectious endocarditis: Clinical sciences
Myocarditis
Pericarditis: Clinical sciences
HIV and AIDS: Pathology review
Malaria: Clinical sciences
Lyme disease: Clinical sciences
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Brucella
Salmonella typhi (typhoid fever)
Epstein-Barr virus (Infectious mononucleosis)
Meningitis and brain abscess: Clinical sciences
Otitis media and externa (pediatrics): Clinical sciences
Pharyngitis, peritonsillar abscess, and retropharyngeal abscess (pediatrics): Clinical sciences
Upper respiratory tract infection
Infectious mononucleosis: Clinical sciences

Decision-Making Tree

Questions

USMLE® Step 2 style questions USMLE

0 of 4 complete

Start
A 55-year-old woman presents to the emergency department with four days of watery stools and diffuse abdominal pain. The patient has been previously treated three times for Clostridioides difficile infection (CDI) with courses of oral vancomycin and oral fidaxomicin. Vital signs are within normal limits. Physical exam shows minimal lower abdominal tenderness to palpation with no rigidity or distention. Stool testing is positive for C. difficile toxin and glutamate dehydrogenase antigen. Computed tomography of the abdomen shows mild inflammatory changes of the colon without sign of bowel dilatation, perforation, or free air. Which of the following is the next best step in the management of this patient?

Transcript

Watch video only

Clostridioides difficile infection, or CDI, is an infection caused by the organism Clostridioides difficile, or C. difficile for short. Infection typically occurs through the fecal-oral route, by ingestion of spores found on contaminated surfaces, in soil, in water, or even on unwashed hands. Once the spores reach the intestines, the GI flora, or microbiota, protects the gut and doesn’t allow C. difficile to proliferate. But, if the diversity of GI flora is disrupted, often by recent antibiotic use, as well as proton pump inhibitors, or hospitalization, C. difficile can overgrow and infect the colon.

As a result, it starts producing toxins A and B, which can damage the gastrointestinal mucosa and eventually cause an inflammatory condition called pseudomembranous colitis. The presentation can range from non-severe disease to severe or even fulminant infection.

Now, if you suspect CDI, the first thing you should do is an ABCDE assessment, to determine if your patient is unstable or stable.

If the patient is unstable, stabilize the airway, breathing, and circulation, which typically requires obtaining IV access, resuscitating with IV fluids, and intubating the patient if you need to secure the airway. Once you stabilize the patient, obtain a focused history and physical examination, and order labs, including CBC, CMP, and lactic acid.

History typically reveals watery diarrhea, usually more than 3 loose stools in 24 hours, which might be associated with mucus or blood, while some may present with ileus. Additionally, individuals may report lower abdominal pain, fever, lethargy, and confusion, as well as recent or current antibiotic use. Physical examination might reveal abdominal distention and tenderness, decreased bowel sounds, and hypotension. Some individuals can present with altered mental status or even shock. Finally, lab results may show an elevated WBC count, serum creatinine, and lactic acid.

Now here’s a high-yield fact! If you suspect CDI in any patient, initiate contact precautions to avoid spreading the infection, and discontinue any inciting antibiotics if possible. You should wash your hands with soap and water before and after patient contact. Remember to avoid using alcohol-based sanitizers, as C. difficile spores are extremely resistant to alcohol.

Alright, now, let’s move on to CDI testing. First, you need to obtain a liquid stool sample, but if there’s minimal diarrhea you can also do a rectal swab. Next, send the sample for a glutamate dehydrogenase antigen test, and C. difficile toxins A and B. If both tests come back negative, rule out CDI and consider an alternative diagnosis. On the flip side, if both tests come back positive, it confirms CDI. However, some individuals can have one positive and one negative test, meaning that the results are inconclusive. In this case, order a nucleic acid amplification test, or NAAT for short, to confirm the result. A positive NAAT testing confirms CDI.

Now, severe clinical manifestations in combination with positive CDI testing can confirm the diagnosis of fulminant CDI, so start supportive care with IV fluids and electrolyte replacement. Additionally, put the patient on complete bowel rest and give total parenteral nutrition or TPN as required. If needed, place a nasogastric tube to access the stomach and relieve upper gastrointestinal distention. Finally, start antibiotics, such as oral or nasogastric vancomycin plus IV metronidazole.

Here’s a high-yield fact to remember! Oral metronidazole is mostly absorbed in the small bowel. But in individuals with non-severe disease, enough will make it to the colon to treat the infection. However, individuals with fulminant CDI might have ileus, which means not enough oral metronidazole will make it to the colon, so IV is the preferred route. On the other hand, oral vancomycin will make its way to the colon without being absorbed, so it’s typically a good choice for all severities of CDI.

Sources

  1. "ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections [published correction appears in Am J Gastroenterol. 2022 Feb 1;117(2):358]." Am J Gastroenterol (2021)
  2. "Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults" Clin Infect Dis (2021)
  3. "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)" Clin Infect Dis (2018)
  4. "Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection" Clin Infect Dis (2011)
  5. "Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis" Clin Infect Dis (2012)